company background image
CNTG logo

Centogene NasdaqGM:CNTG Stock Report

Last Price

US$0.37

Market Cap

US$10.8m

7D

1.8%

1Y

-52.5%

Updated

16 Jun, 2024

Data

Company Financials +

CNTG Stock Overview

Provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific.

CNTG fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Centogene N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Centogene
Historical stock prices
Current Share PriceUS$0.37
52 Week HighUS$1.98
52 Week LowUS$0.34
Beta-0.68
1 Month Change0.19%
3 Month Change-47.04%
1 Year Change-52.52%
3 Year Change-96.24%
5 Year Changen/a
Change since IPO-97.35%

Recent News & Updates

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Recent updates

Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Feb 16
Centogene N.V.'s (NASDAQ:CNTG) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Dec 21
Centogene N.V. (NASDAQ:CNTG) Might Not Be As Mispriced As It Looks

Centogene GAAP EPS of -€0.28, revenue of €10.32M

Jul 15

Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Nov 25
Is Centogene (NASDAQ:CNTG) Using Debt In A Risky Way?

Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Jun 29
Is Centogene (NASDAQ:CNTG) Using Debt Sensibly?

Centogene reports Q1 results

Jun 16

Centogene, Alector initiate EFRONT study in frontotemporal dementia

Jun 02

Centogene to nominate Rene Just as CFO at the upcoming Annual General Meeting

May 26

Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)

Apr 17
Need To Know: Analysts Are Much More Bullish On Centogene N.V. (NASDAQ:CNTG)

What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?

Mar 05
What Percentage Of Centogene N.V. (NASDAQ:CNTG) Shares Do Insiders Own?

Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year

Jan 29
Update: Centogene (NASDAQ:CNTG) Stock Gained 11% In The Last Year

Is Centogene (NASDAQ:CNTG) A Risky Investment?

Dec 18
Is Centogene (NASDAQ:CNTG) A Risky Investment?

Centogene reports Q3 results

Dec 16

Shareholder Returns

CNTGUS HealthcareUS Market
7D1.8%-0.007%1.2%
1Y-52.5%6.1%20.8%

Return vs Industry: CNTG underperformed the US Healthcare industry which returned 6.1% over the past year.

Return vs Market: CNTG underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is CNTG's price volatile compared to industry and market?
CNTG volatility
CNTG Average Weekly Movement10.4%
Healthcare Industry Average Movement6.5%
Market Average Movement5.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.9%

Stable Share Price: CNTG's share price has been volatile over the past 3 months.

Volatility Over Time: CNTG's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2006444Kim Strattonwww.centogene.com

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options.

Centogene N.V. Fundamentals Summary

How do Centogene's earnings and revenue compare to its market cap?
CNTG fundamental statistics
Market capUS$10.75m
Earnings (TTM)-US$38.03m
Revenue (TTM)US$51.95m

0.2x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CNTG income statement (TTM)
Revenue€48.54m
Cost of Revenue€30.84m
Gross Profit€17.70m
Other Expenses€53.23m
Earnings-€35.53m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.23
Gross Margin36.46%
Net Profit Margin-73.21%
Debt/Equity Ratio-260.1%

How did CNTG perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.